Meitheal Pharmaceuticals, Inc.
Meitheal, founded in 2017 in Chicago, develops and commercializes generic injectables and since 2022 has expanded into fertility, biologics, and branded products. The company currently markets 70+ FDA-approved medicines across therapeutic areas including anti-infectives, oncology, intensive care, and fertility. As of September 2025, its pipeline has 40 products in R&D, and 23 under FDA review,